Amphastar Pharmaceuticals, Inc. (AMPH) stock
AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3033% below fair value
$28.60−0.46 (-1.58%)
Close on Nov 11, 2026Market cap $1.22BP/E 13.0Yield –
Amphastar Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Amphastar Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 46.8%. For fiscal 2025 it was 49.5%, against 51.1% the year before. The highest annual figure on record is 54.5% in fiscal 2023.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.5% | −1.6 |
| FY2024 | Dec 31, 2024 | 51.1% | −3.4 |
| FY2023 | Dec 31, 2023 | 54.5% | +4.6 |
| FY2022 | Dec 31, 2022 | 49.9% | +4.2 |
| FY2021 | Dec 31, 2021 | 45.6% | +4.7 |
| FY2020 | Dec 31, 2020 | 41.0% | +0.0 |
| FY2019 | Dec 31, 2019 | 40.9% | +4.6 |
| FY2018 | Dec 31, 2018 | 36.3% | −1.4 |
| FY2017 | Dec 31, 2017 | 37.7% | −3.2 |
| FY2016 | Dec 31, 2016 | 40.8% | +10.1 |
| FY2015 | Dec 31, 2015 | 30.8% | +6.4 |
| FY2014 | Dec 31, 2014 | 24.4% | −13.5 |
| FY2013 | Dec 31, 2013 | 37.9% | −6.3 |
| FY2012 | Dec 31, 2012 | 44.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 48.0% | −3.4 |
| Q2 FY2026 | Jun 30, 2026 | 50.8% | +1.2 |
| Q1 FY2026 | Mar 31, 2026 | 41.1% | −8.9 |
| Q4 FY2025 | Dec 31, 2025 | 46.8% | +0.3 |
| Q3 FY2025 | Sep 30, 2025 | 51.4% | −1.9 |
| Q2 FY2025 | Jun 30, 2025 | 49.6% | −2.6 |
| Q1 FY2025 | Mar 31, 2025 | 50.0% | −2.4 |
| Q4 FY2024 | Dec 31, 2024 | 46.5% | −7.5 |
| Q3 FY2024 | Sep 30, 2024 | 53.3% | −6.7 |
| Q2 FY2024 | Jun 30, 2024 | 52.2% | +2.3 |
| Q1 FY2024 | Mar 31, 2024 | 52.4% | −0.3 |
| Q4 FY2023 | Dec 31, 2023 | 54.0% | +1.3 |
| Q3 FY2023 | Sep 30, 2023 | 60.0% | +11.3 |
| Q2 FY2023 | Jun 30, 2023 | 49.9% | −1.4 |
| Q1 FY2023 | Mar 31, 2023 | 52.7% | +6.4 |
| Q4 FY2022 | Dec 31, 2022 | 52.7% | +6.2 |
| Q3 FY2022 | Sep 30, 2022 | 48.7% | +3.1 |
| Q2 FY2022 | Jun 30, 2022 | 51.3% | +4.7 |
| Q1 FY2022 | Mar 31, 2022 | 46.4% | +2.8 |
| Q4 FY2021 | Dec 31, 2021 | 46.5% | +8.1 |
| Q3 FY2021 | Sep 30, 2021 | 45.6% | +1.9 |
| Q2 FY2021 | Jun 30, 2021 | 46.6% | +7.9 |
| Q1 FY2021 | Mar 31, 2021 | 43.6% | +0.1 |
| Q4 FY2020 | Dec 31, 2020 | 38.4% | −1.6 |
| Q3 FY2020 | Sep 30, 2020 | 43.8% | −0.2 |
| Q2 FY2020 | Jun 30, 2020 | 38.7% | −2.3 |
| Q1 FY2020 | Mar 31, 2020 | 43.5% | +4.8 |
| Q4 FY2019 | Dec 31, 2019 | 40.0% | +1.4 |
| Q3 FY2019 | Sep 30, 2019 | 44.0% | +5.3 |
| Q2 FY2019 | Jun 30, 2019 | 41.0% | +4.3 |
| Q1 FY2019 | Mar 31, 2019 | 38.7% | +9.7 |
| Q4 FY2018 | Dec 31, 2018 | 38.7% | +4.8 |
| Q3 FY2018 | Sep 30, 2018 | 38.7% | +3.2 |
| Q2 FY2018 | Jun 30, 2018 | 36.7% | −4.2 |
| Q1 FY2018 | Mar 31, 2018 | 29.1% | −11.2 |
| Q4 FY2017 | Dec 31, 2017 | 33.9% | +2.5 |
| Q3 FY2017 | Sep 30, 2017 | 35.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 40.9% | – |
| Q1 FY2017 | Mar 31, 2017 | 40.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 31.4% | – |
See a number that looks wrong?